Navigation Links
Bioniche Pharma Launches Ibutilide Fumarate Injection
Date:1/12/2010

LAKE FOREST, Ill., Jan. 12 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals announced today the launch of Ibutilide Fumarate Injection, the generic equivalent of Corvert® from Pfizer Inc.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)

"The addition of Ibutilide Fumarate Injection further demonstrates Bioniche Pharma's continued growth and dedication to a consistently expanding portfolio of injectables," said George Zorich, President, US Operations for Bioniche Pharma.

Bioniche Pharma will supply Ibutilide Fumarate Injection in 0.1 mg/mL, 10mL vials.

This product has a boxed warning relating to proarrhythmic effects including potentially fatal arrhythmias (e.g., polymorphic ventricular tachycardia) and consideration for use in patients with chronic atrial fibrillation. Please refer to the Bioniche Pharma website at www.bionichepharma.com for the complete prescribing information for this product, including the boxed warning.

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets. The company's growth is fueled by an internal development pipeline and an aggressive acquisition strategy for products. Bioniche Pharma was acquired in February 2006 by RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois. More information about Bioniche Pharma can be found at www.bionichepharma.com.

Corvert® is a registered trademark of Pharmacia & Upjohn Company LLC

SOURCE Bioniche Pharma

RELATED LINKS
http://www.bionichepharma.com

'/>"/>

SOURCE Bioniche Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
2. Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
3. Bioniche Pharma and Academic Pharmaceuticals, Inc. Announce the Introduction of Sotalol Hydrochloride Injection
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
(Date:5/24/2016)... , May 24, 2016 ... Markt gebracht, die es Ärzten erlaubt, ihre Expertise ... behandeln: MDLinking kombiniert Live Streaming mit einer Instant-Messaging-Funktion ... zu kommunizieren. Mediziner in Europa, Afrika, Asien und ... bereits für die Plattform registriert. Information ...
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und demonstriert ... in ‚ausgezeichneter plus guter , ...    ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... heute neue positive Daten von der MORA-Studie der ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... ... seen a significant spike in their clients' employee participation for their wellness initiatives. ... screening by implementing a high-deductible health plan with outcome-based deductible incentives. As a ...
(Date:5/25/2016)... Jersey (PRWEB) , ... May 25, 2016 , ... ... technology firm will be selling the device branded as Stern’s Real Time Monitoring ... geared to bedbugs to the hotel and motel industry, colleges for use in dormitories, ...
(Date:5/24/2016)... ... May 24, 2016 , ... PhishLine, the best-in-class, enterprise ... company as Vice President of Sales. Cifolelli’s primary responsibilities include management of ... the rapidly expanding field of organizational social engineering. , “We are delighted ...
(Date:5/24/2016)... ... ... Jericho Project has named LaToya Williams-Belfort to the position of Chief Development and Communications ... the nationally-acclaimed nonprofit, working closely with CEO Tori Lyon and the Board of Directors ... , “LaToya Williams-Belfort is joining Jericho at an exciting time of growth and ...
(Date:5/24/2016)... , ... May 24, 2016 , ... How to Write ... Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the major ... human error will ever be totally eliminated, many human performance problems can be prevented. ...
Breaking Medicine News(10 mins):